Radiation response modification following molecular inhibition of epidermal growth factor receptor signaling

Seminars in Radiation Oncology

Volumn 11, Issue 4, 2001, Pages 281-289

  Harari, Paul M ^a,b   Huang, Shyh Min ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; GEFITINIB; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INVASION; CANCER RADIOTHERAPY; COLORECTAL CANCER; CORRELATION FUNCTION; DNA DAMAGE; DOWN REGULATION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIVITY; SIGNAL TRANSDUCTION;

EID: 0034788824     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1053/srao.2001.26027     Document Type: Article

References (37)

1. Epidermal growth factor
2. Receptor protein-tyrosine kinases and their signal transduction pathways
3. Signal transduction by receptors with tyrosine kinase activity
4. The epidermal growth factor receptor (EGFR) - A new target in cancer therapy
5. New technologies in epidermal growth factor receptor-targeted cancer therapy
6. A Phase II, multicenter study of the epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor, CP-358,774, in patients with advanced squamous cell carcinoma of the head and neck
7. Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity
8. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy
9. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model
10. Phase I studies of anti-epidermal growth factor receptor (EGFR) chimeric monoclonal antibody C225 in patients with EGFR overexpressing tumors
11. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck
12. Modulation of radiation response following epidermal growth factor receptor blockade in squamous cell carcinomas: Inhibition of damage repair, cell cycle kinetics and tumor angiogenesis
13. Treatment of human intracranial gliomas with chimeric monoclonal antibody against the epidermal growth factor receptor increases survival of nude mice when treated concurrently with irradiation
14. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody
15. Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation
16. Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide
17. Physical interaction between epidermal growth factor receptor and DNA-dependent protein kinase in mammalian cells
18. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors
19. Anti-epidermal growth factor receptor antibody C225 inhibits angiogensis in human transitional cell carcinoma growing orthotopically in nude mice
20. Induction of the angiogenic modulator fibroblast growth factor-binding protein by epidermal growth factor is mediated through both MEK/ERK and p38 signal transduction pathways
21. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms
22. Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinomas of the head and neck
23. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor
24. Combination of ZD1839 ("Iressa"), and EGFR-TKI, and radiotherapy increases antitumour efficacy in a human colon cancer xenograft model
25. ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), enhances radiation (RT)-induced cytotoxicity in human pancreatic and cholangiocarcinoma cell lines in vitro
26. Intermittent oral ZD1839 (Iressa), a novel epidermal growth factor receptor tyrosine kinase inhibitor (Egfr-Tki), shows evidence of good tolerability and activity: Final results from a phase I study
27. Continuous administration of ZD1839 (Iressa), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in patients with five selected tumor types: Evidence of activity and good tolerability
28. New therapeutic agents targeting the epidermal growth factor receptor
29. Radiosensitization of human breast cancer cells by a novel erbB family receptor tyrosine kinase inhibitor
30. The advancement of clinical trials for cancer patients with tumors demonstrating EGFR overexpression
31. Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers
32. Continued response following treatment with IMC- C225, an EGFr MoAb, combined with RT in advanced head and neck malignancies
33. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin
34. Safety profile of the monoclonal antibody (MoAb)IMC-C225, an anti-epidermal growth factor receptor (EGFr) used in the treatment of EGFr-positive tumors
35. Low immunogenicity of a chimeric monoclonal antibody (MoAb), IMC-C225, used to treat epidermal growth factor-positive tumors
36. Epidermal growth factor receptor inhibition in cancer therapy: Biology, rationale and preliminary clinical results
37. Modulation of molecular targets to enhance radiation